Humanized Liver Mice Model Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global incidence of liver cirrhosis is on the rise, driven by various risk factors, including Hepatitis B virus (HBV), Hepatitis C virus (HCV), and liver cancer. According to global statistics, 257 million people were infected with chronic HBV in 2015, with Asia and Africa experiencing high endemic prevalence rates of over 8%. Liver cancer ranks as the 7th most common cancer worldwide, with approximately 841,080 new cases diagnosed annually, as per Glococan 2018 data.

The growing prevalence of liver cirrhosis is driving the demand for humanized liver mice models used in research studies focused on treatment and therapy development for this condition. Several key factors are contributing to the growth of the humanized liver mice model market:

Technological Advancement and Development of New Humanized Liver Mice Models

Researchers are actively working on developing new humanized liver mice models with improved reliability and consistency. Earlier models used simple immunodeficient mice implanted with human liver cells or hepatic cancer cells, but the results were inconsistent. Advancements have led to the development of immunodeficient mice that naturally replace their liver with human liver cells, resulting in more stable humanized liver mice models. Researchers are also exploring the use of PPARalpha and AFC8-based mice models, further enhancing the range of options.

Increasing Number of FDA Approvals for Hepatitis Drugs

The rising number of drug approvals, particularly for hepatitis treatments, indicates the volume of research and toxicity studies conducted using pre-clinical models like humanized liver mice. While there were only four drug approvals for hepatitis treatment from 2011 to 2014, the following three years (2015-2017) saw approximately eight approvals, highlighting the significance of these models in drug development.

High Cost of Humanized Liver Mice Models and Shipping

Despite their importance, humanized liver mice models come with a significant cost. Immunodeficient mice for liver studies range from US$140 to US$500, while chimeric humanized liver mice models with substantial human hepatocyte replacement can cost between US$2,500 and US$3,500. Additionally, specialized shipping containers and protocols add to the overall cost, making these models expensive for researchers.

Focus on 3Rs Principles

The 3Rs principles (replace, reduce, and refine) are influencing the use of animals for testing, including humanized liver mice models. These principles encourage the replacement of animal models with alternatives like 2D and 3D cell lines or lab-on-chip devices. They also emphasize reducing the number of animals used and refining experiment protocols to minimize animal suffering without compromising research outcomes.

Segmentation

The report provides an extensive categorization of the humanized liver mice model market, considering various factors such as model type, application, end-user, and geographical region. Model types encompass uPA-SCID Mice, FRG-KO Mice, TK-NOG mice, and other models. In terms of applications, the humanized liver mice model market is divided into pharmacokinetics studies, in-vivo liver toxicity testing, drug metabolism studies, and other relevant applications.

Competitive Landscape

The humanized liver mice model market features key players like Yecuris Corporation, PhoenixBio Group, Beijing Vitalstar Biotechnology Co. Ltd, Hera BioLabs, Taconic Biosciences, Inc, University of Massachusetts Medical School, Oncodesign, University of Nebraska Medical Center, and Jackson Laboratory.


This product will be delivered within 1-3 business days.